GB201615908D0 - Pharmaceautical composition - Google Patents
Pharmaceautical compositionInfo
- Publication number
- GB201615908D0 GB201615908D0 GBGB1615908.9A GB201615908A GB201615908D0 GB 201615908 D0 GB201615908 D0 GB 201615908D0 GB 201615908 A GB201615908 A GB 201615908A GB 201615908 D0 GB201615908 D0 GB 201615908D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceautical
- composition
- pharmaceautical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615908.9A GB2554088A (en) | 2016-09-19 | 2016-09-19 | Pharmaceautical composition |
| EA201990501A EA201990501A1 (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION |
| UAA201902773A UA124240C2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| US16/334,156 US20190388436A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MYPI2019001314A MY202030A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| ES17777636T ES2841649T5 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| NZ752434A NZ752434B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| EP19199776.6A EP3610877A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| EP17777636.6A EP3515451B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| PCT/GB2017/052762 WO2018051131A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MX2019003103A MX2019003103A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition. |
| PE2019000675A PE20191044A1 (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION |
| AU2017328908A AU2017328908B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| EP19199786.5A EP3607951A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| JP2019515271A JP6781832B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| MYPI2023001168A MY210122A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| CN201780057285.4A CN109789151A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| CN202110273940.8A CN113069417A (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| BR112019005113-9A BR112019005113B1 (en) | 2016-09-19 | 2017-09-18 | PHARMACEUTICAL COMPOSITION |
| CA3037257A CA3037257C (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical compositions comprising beclomethasone dipropionate, and formoterol fumarate dihydrate |
| PH1/2019/500577A PH12019500577B1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| KR1020197010383A KR102279445B1 (en) | 2016-09-19 | 2017-09-18 | pharmaceutical composition |
| GEAP201715034A GEP20217240B (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| CN202310774818.8A CN116898804A (en) | 2016-09-19 | 2017-09-18 | pharmaceutical composition |
| IL265349A IL265349B2 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
| CONC2019/0002555A CO2019002555A2 (en) | 2016-09-19 | 2019-03-19 | Pharmaceutical composition |
| ZA2019/02052A ZA201902052B (en) | 2016-09-19 | 2019-04-02 | Pharmaceutical composition |
| US16/582,964 US20200016175A1 (en) | 2016-09-19 | 2019-09-25 | Pharmaceutical composition |
| US16/582,710 US20200016174A1 (en) | 2016-09-19 | 2019-09-25 | Pharmaceutical composition |
| JP2020042092A JP6980050B2 (en) | 2016-09-19 | 2020-03-11 | Pharmaceutical composition |
| AU2020202651A AU2020202651C1 (en) | 2016-09-19 | 2020-04-20 | Pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615908.9A GB2554088A (en) | 2016-09-19 | 2016-09-19 | Pharmaceautical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201615908D0 true GB201615908D0 (en) | 2016-11-02 |
| GB2554088A GB2554088A (en) | 2018-03-28 |
Family
ID=57288606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1615908.9A Withdrawn GB2554088A (en) | 2016-09-19 | 2016-09-19 | Pharmaceautical composition |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2554088A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221867A1 (en) * | 2020-01-28 | 2022-12-02 | Chiesi Farm Spa | PRESSURIZED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
-
2016
- 2016-09-19 GB GB1615908.9A patent/GB2554088A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2554088A (en) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201621987D0 (en) | Novel composition | |
| GB201600075D0 (en) | Immunogenci composition | |
| PL3443034T3 (en) | Composition | |
| GB201621685D0 (en) | Novel composition | |
| GB201612658D0 (en) | Composition | |
| GB201617908D0 (en) | Composition | |
| GB201611782D0 (en) | Composition | |
| ZA201901222B (en) | Composition comprising duddingtonia flagrans | |
| GB2557410B (en) | Composition | |
| GB201620701D0 (en) | Novel composition | |
| GB201612359D0 (en) | Composition | |
| GB201620846D0 (en) | Composition | |
| GB201615908D0 (en) | Pharmaceautical composition | |
| GB201607924D0 (en) | Composition | |
| GB201620914D0 (en) | Composition | |
| GB201620792D0 (en) | Composition | |
| GB201619630D0 (en) | Composition | |
| GB201618062D0 (en) | Composition | |
| GB201616772D0 (en) | Composition | |
| GB201616785D0 (en) | Composition | |
| GB201615461D0 (en) | Composition | |
| GB201615463D0 (en) | Composition | |
| GB201615383D0 (en) | Composition | |
| GB201615045D0 (en) | Composition | |
| GB201614231D0 (en) | Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |